This concerning trend is gaining momentum: major hospital networks are increasingly resistant to adopting innovative orthopedic devices. Metaphorically speaking, these systems have developed "antibodies" that fend off new products, prioritizing cost control and evidence-based value over rapid innovation.
This shift, driven by consolidation and rigorous evaluation processes, poses significant challenges for device manufacturers and sales teams.At the heart of this resistance is the rise of the Value Analysis Committee (VAC) era. Gone are the days when surgeons held sway over purchasing decisions in regional hospitals. Today, consolidated health systems rely on VACs to scrutinize submissions, with only about 5% of proposed products gaining approval.
Traditional sales approaches, like direct pitches to surgeons, simply no longer cut it in this environment.
This "antibody" development isn't just anecdotal—it's a systemic response to rising costs and regulatory pressures. Large groups are fortifying their defenses through data-driven reviews, demanding robust clinical outcomes, cost-benefit analyses, and long-term value proofs before greenlighting anything new. For small ortho companies...
